All the news Showing 10 of 46 articles from: Previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Investigational noninterferon HCV treatment effective across patient groups Internal Medicine News / 30 May 2013 Vaniprevir boosts interferon/ribavirin response rate for prior non-responders with cirrhosis Liz Highleyman / 13 May 2013 The next-generation HCV protease inhibitor vaniprevir (MK-7009) increased post-treatment sustained response rates for previously treated genotype 1 chronic hepatitis C patients with liver cirrhosis when added to pegylated interferon plus ribavirin, researchers reported at ... AbbVie interferon-free combination cures over 90% of hepatitis C genotype 1 Keith Alcorn / 26 April 2013 A four-drug combination of direct acting antivirals developed by AbbVie cured hepatitis C infection in over 90% of participants in the AVIATOR study, without the need for the use of interferon, researchers reported ... Sofosbuvir + ribavirin cures most genotype 2 hepatitis C, but genotype 3 response is lower Liz Highleyman / 26 April 2013 A dual oral regimen containing the hepatitis C nucleotide polymerase inhibitor sofosbuvir plus ribavirin produced high sustained virological rates overall, but this was driven by very good response amongst people with HCV genotype ... Daclatasvir/asunaprevir effective in difficult-to-treat HCV populations Healio Hepatology / 09 April 2013 Telaprevir shows promise in black patients with genotype 1 HCV Healio / 12 March 2013 Victrelis (boceprevir) label updates FDA / 18 February 2013 Gilead Provides Update on Hepatitis C Development Programs Gilead press release / 08 January 2013 Is a simple sofosbuvir plus ribavirin regimen suitable for difficult-to-treat hepatitis C patients? Liz Highleyman / 12 December 2012 An all-oral dual regimen of sofosbuvir (GS-7977) plus full-dose ribavirin was well-tolerated and produced four-week post-treatment sustained response in approximately three-quarters of previously untreated genotype 1 chronic hepatitis C patients in an inner-city pilot ... Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring Liz Highleyman / 05 December 2012 Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivo), researchers reported ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive